Publications:
Our Research

Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines

The Novavax Heterologous COVID Booster Demonstrates Lower Reactogenicity Than mRNA: A Targeted Review

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-cov-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

Biodistribution of the Saponin-Based Adjuvant Matrix-M™ Following Intramuscular Injection in Mice

XBB.1.5 spike protein COVID‑19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses

Diet-induced obesity and diabetes enhance mortality and reduce vaccine efficacy for SARS-CoV-2

A Phase 3, randomized, non‑inferiority study of a heterologous booster dose of SARS CoV‑2 recombinant spike protein vaccine in adults

A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses